http://www.gene.com/media/product-in...pment-timeline
and this is the JCO article:
Four-Year Follow-Up of Trastuzumab Plus Adjuvant
Chemotherapy for Operable Human Epidermal Growth
Factor Receptor 2–Positive Breast Cancer: Joint Analysis of
Data From NCCTG N9831 and NSABP B-31